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Abstract 
Objectives: Deep interarytenoid notch (DIN) is a congenital variation of the larynx often 
associated with dysphagia and aspiration (DA) in young children. Feeding therapy with 
thickeners and surgical management with injection larygoplasty (IL) are used with various 
efficacies. Thickeners address the functional domain and IL addresses the anatomical domain of 
treatment. Our objective was to evaluate DIN patients managed with both interventions.  
Methods: We conducted a retrospective pilot descriptive study of DIN patients with DA aged 1-
3 years receiving thickeners and IL. Patients received a systematic weekly reduction of 
thickeners based on clinical signs and symptoms of DA. The outcomes were assessed by the 
rate of thickener level reduction and DA-related sign/symptom frequency achieved at 6 months 
post-treatment.  
Results: Thirteen patients with DIN associated DA were analyzed.  Thickener scores improved 
from an average of 5.76 (3/4 honey) to 2.15 (thin) (p = 0.001). DA-related signs/symptoms 
frequency improved from an average of 3.3 to 0.84 (p = 0.05).  
Conclusions: These findings suggest that treatment of DIN associated DA with a combination of 
thickeners and IL results in significant clinical improvements in young children. 
Keywords: deep interarytenoid notch; injection laryngoplasty; thickener; dysphagia; aspiration; 
laryngeal cleft 
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Introduction 
The incidence of dysphagia has been increasing in children, and a portion of these patients are 
found to have a laryngeal cleft on further evaluation[1]. Type 1 laryngeal clefts (LC1) are the 
most common and mild form of this defect, as described by the Benjamin and Inglis 
classification system[2]. LC1s are defined as defects in the interarytenoid area extending no 
further inferiorly than the true vocal cords. The defect is in the interarytenoid musculature, 
with or without absence of the overlying mucosa. A normal interarytenoid notch height (IANH) 
in otherwise healthy young children is greater than 3 mm, and on average 3.5 mm[3]. A sub-
classification of LC1s has emerged more recently which includes shorter interarytenoid notch 
heights (less than 3 mm above the glottis) with normal musculature[4], which we term deep 
interarytenoid notches (DIN)[5]. Although DINs have not been described much in the literature, 
our institutional experience is that they are frequently found in children presenting with DA[6] 
to an aerodigestive multidisciplinary clinic. In 2013, PCH ADC found that 24% (114/471) of 
young patients presenting with dysphagia and aspiration (DA) were diagnosed with DIN. DINs 
are a normal congenital variant and their significance in the symptomatology of patients is 
unclear.  
The presentation of LC1 commonly involves a combination of both airway and feeding 
difficulties [7], including aspiration/penetration, recurrent pneumonias, respiratory distress, 
stridor, dysphagia, feeding problems, and failure to thrive. Penetration is defined as the 
passage of material into the larynx but not below the level of the vocal folds, whereas 
aspiration is when material enters the airway below the level of the vocal folds [8]. Either can 
occur with LC1/DIN. Additionally, laryngeal cleft patients with aspiration/penetration are also 
found to have swallow dysfunction across all phases of swallow (oral phase, pharyngeal phase, 
etc.)[9]. 
Initial workup for these patients includes modified barium swallow (MBS) evaluation, where a 
speech and language pathologist (SLP) administers various consistencies of food containing 
radiolabeled tracer seen under fluoroscopy. When MBS is inconclusive, patients can also 
undergo functional endoscopic evaluation of swallowing (FEES)[10]. The abnormal MBS/FEES 
2 
 
findings coupled with the presenting signs and symptoms often leads to direct laryngoscopy, 
the gold-standard diagnostic test for laryngeal clefts/DINs[2,11]. These patients can also have 
coincident pathologies contributing to their symptoms including laryngomalacia, 
gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EOE), 
tracheobronchomalacia, reactive airway disease (RAD), and oral/motor delays[4]. Accordingly, a 
multidisciplinary approach in the evaluation and treatment of patients presenting with DA has 
gained traction[12].  
Treatment for these clefts can involve surgical intervention to address the anatomical defect or 
functional therapy utilizing feeding therapy with dysphagia management. These patients can 
also be treated medically for comorbid conditions, such as GERD and RAD, to help alleviate 
aerodigestive inflammation contributing to DA and to improve swallowing function[13,14]. One 
method of surgical intervention consists of injection laryngoplasty (IL), which has become 
popular lately due to the relative safety and effectiveness of the procedure[15,16,17,18]. IL 
involves injecting an aqueous gel into the interarytenoid space to provide temporary bulk to 
the interarytenoid area. Feeding therapy with dysphagia management includes manipulating 
the bolus size and flow via drinking utensil changes, thickened liquids, and addressing oral 
phase deficits which might contribute to pharyngeal phase dysphagia[19]. Many studies have 
utilized thickeners in the management of laryngeal cleft associated DA[7,17,18,20,21,22].  
We present an approach involving both IL and thickened liquids aimed at rapid thickener 
reduction and sign/symptom improvement. Many of our patients are also on concomitant 
medical therapy for comorbid disease.  
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Methods 
We performed a descriptive pilot study through retrospective chart review of pediatric patients 
aged 1-3 years old who presented to the PCH ADC between January 2015 and September 2016 
with DA and were diagnosed with DIN. PCH ADC uses a multidisciplinary approach for such 
patients. They routinely undergo subspecialty clinic evaluation (otolaryngology, 
gastroenterology, pulmonology, and SLP), triple endoscopy as indicated (direct laryngoscopy, 
esophagogastroduodenoscopy (EGD), and bronchoscopy), and feeding evaluation (using MBS 
and sometimes FEES). Decision for IL is made at the time of diagnosis during endoscopy 
procedures and is completed at that time or scheduled as a separate procedure. This decision is 
made by the otolaryngologist based on history, clinical symptoms, and other anatomical 
findings, including depth of DIN as observed by direct laryngoscopy.  
We examined the clinical outcomes of the patients who were treated with both IL and PCH’s 
proprietary thickener weaning protocol (TWP) (detailed below). Sixty one charts with the 
diagnosis of DIN were reviewed. Inclusion criteria included age 1-3 years at the time of 
diagnosis of DIN, IL, and having started TWP within 6 months of IL. Patients were excluded if 
they had any history of severe neurodevelopmental delay, prior esophageal surgery, 
endoscopic repair of DIN, or if the time interval between IL and start of TWP was greater than 6 
months.  
The primary outcome was the rate of thickener level reduction over the 6 months of TWP. 
Terminology used to describe liquid viscosity is consistent with the National Dysphagia Diet[23]. 
These include spoon-thick (>1750 centipoise (cP)), honey-like (351-1750 cP), nectar like (51-350 
cP), and thin (1-50 cP). Our institution also found the need to describe ‘half’ and ‘three quarter’ 
recipes when using SimplyThick (SimplyThick, LLC) gel and/or infant cereal to thicken liquids, 
because children often showed DA when transitioning from honey-like to nectar-like liquids. 
Use of a more gradual thickener wean is well tolerated by children and many are able to 
advance to a thin-fluid diet[24]. To obtain measurable and quantifiable information for the 
purposes of our study, our institution developed a numerical scale to quantify thickened liquids 
and help describe severity of dysphagia (table 1). The scores range from ultrathin (1) to pudding 
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consistency (9). Higher scores indicate thicker liquids and more severe dysphagia. The SLP’s diet 
recommendation were scored according to the aforementioned table based on the thinnest 
consistency the patient was able to tolerate without experiencing aspiration/penetration. 
The secondary outcome measure was the reduction of thickener level (clinically) and of DA-
related signs/symptoms over the 6 months of TWP. This included pulmonary and 
gastrointestinal signs/symptoms thought to be manifestations of the DIN. A total of 17 signs 
and symptoms (12 gastrointestinal and 5 pulmonary) were scored using a questionnaire where 
frequency was reported on a numerical scale (0-4) based on parents’ recall (table 2). Baseline 
thickener levels and signs/symptoms were compared to the corresponding values at 6 months 
into TWP therapy (or sooner if the patient was able to be weaned completely off the 
thickeners).  
The Wilcoxon signed rank test was used to compare pre-treatment and post-treatment results 
of the primary and secondary outcomes, and a p-value of <0.05 was considered statistically 
significant. The sub-stratification groups were compared using the Wilcoxon rank sum test, 
again using a p-value of <0.05 as statistically significant.  
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Table 1: Thickener consistency/liquid viscosity scores 
MBS Thickness 
Recommendation Description Score 
Ultrathin  Equal to water, breastmilk 1 
Thin  Equal to milk or formula 2 
½ nectar  1 pack of Simply Thick nectar gel in 8 fluid ounces or  1 teaspoon of infant cereal per 1 fluid ounce 3 
¾ nectar  1 pack of Simply Thick nectar gel in 6 fluid ounces or  1.5 teaspoons of infant cereal per 1 fluid ounce 4 
Nectar  1 pack of Simply Thick nectar gel in 4 fluid ounces or  2 teaspoons of infant cereal per 1 fluid ounce 5 
¾ honey  1 pack of Simply Thick honey gel in 6 fluid ounces or  2.5 teaspoons of infant cereal per 1 fluid ounce 6 
Honey  1 pack of Simply Thick honey gel in 4 fluid ounces or  3 teaspoons of infant cereal per 1 fluid ounce 7 
Double honey/ 
spoon thick  
2 packs of Simply Thick honey gel in 8 fluid ounces or  
4 teaspoons of infant cereal per 1 fluid ounce 8 
Pudding  3 packs of Simply Thick honey gel in 4 fluid ounces 9 
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Table 2: Dysphagia and aspiration questionnaire  
How often does your child have the following signs/symptoms? 
Cough  0 1 2 3 4 
Cough with food 0 1 2 3 4 
Cough with liquid 0 1 2 3 4 
Night time cough 0 1 2 3 4 
Nasal Congestion 0 1 2 3 4 
Chest congestion  0 1 2 3 4 
Wheezing  0 1 2 3 4 
Choke with food 0 1 2 3 4 
Choke with liquid 0 1 2 3 4 
Choke Without feed   0 1 2 3 4 
Gag with food 0 1 2 3 4 
Gag with liquid 0 1 2 3 4 
Gag Without feed 0 1 2 3 4 
Vomit 0 1 2 3 4 
Feeding refusal 0 1 2 3 4 
Wet voice 0 1 2 3 4 
Hoarse voice 0 1 2 3 4 
(0-never, 1-monthly, 2- weekly 3-daily, 4-multiple times per day) 
 
  
7 
 
Thickener wean protocol (TWP): 
Phoenix Children’s Hospital TWP[4] methodology was developed to treat patients with 
persistent dysphagia and aspiration who remain dependent on thickened liquids to reduce risk 
of aspiration.  The goal of the intervention is to achieve the least restrictive liquid diet for each 
patient. The TWP is designed to reduce liquid viscosity by increasing the amount of liquid mixed 
with the thickening agent. Patients are seen for weekly feeding therapy with dysphagia 
management.  
Injection Laryngoplasty (IL): 
After endotracheal intubation of the patient, a Lindholm laryngoscope is introduced to the 
vallecula. Vocal cord spreaders are used to retract apart the true and false vocal cords allowing 
for better visualization of the interarytenoid space. The endotracheal tube is pulled back to the 
level of the hypopharynx. An endoscopic needle is then used to deliver 0.3-0.6 ccs of hyaluronic 
acid into the interarytenoid submucosal space. Patients are able to return to normal activity the 
same day following the procedure. The patient’s prior diet is resumed post-operatively and they 
are scheduled to follow-up in 4 weeks to be reassessed with MBS to determine if TWP can be 
started.  
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Results 
Thirteen patients fit the criteria for the study out of 61 patients identified based on diagnosis of 
DIN. Their mean age at diagnosis was 21.6 months and 5/13 (38.4%) were males (Table 3). 
Common comorbidities included GERD (76.9%) and asthma/RAD (46.2%), as well as 3 cases of 
enteral feeding tubes (23.1%), 2 cases of congenital heart defects (15.3%), and one case of 
Down syndrome (7.7%). There were no instances of EOE, esophageal stricture, peptic ulcer 
disease, bronchiolitis, or intrauterine drug exposure. Common medications for comorbid 
diseases included bronchodilators (69.2%), inhaled corticosteroids (61.5%), proton pump 
inhibitors (PPI) (53.8%), H-2 receptor antagonists (23.1%), and Leukotriene receptor antagonists 
(23.1%).  
All patients received a diagnostic MBS and did not require further evaluation with FEES. Seven 
patients demonstrated aspiration and 6 patients demonstrated penetration. Of the 7 patients 
who aspirated, 4 had silent aspiration. Eleven of 13 patients received triple endoscopy (direct 
laryngoscopy, bronchoscopy, and EGD). One patient underwent just direct laryngoscopy with 
bronchoscopy because they had little to no gastrointestinal (GI) symptoms. Another patient 
underwent just direct laryngoscopy with EGD due to few respiratory symptoms.  
The overall reduction in thickener level was 3.61 (SD = 1.9), from an average pretreatment level 
of 5.76 (¾ honey) to a posttreatment level of 2.15 (thin) (p = 0.001). Figure 1 illustrates each 
individual subject’s thickener score over the course of therapy. The sign/symptom frequency 
also reduced by 2.46 (SD = 4.2), from average score of 3.3 to 0.84 (p = 0.05).  
The patients were then sub-stratified based on initial DA severity, as determined by their 
baseline thickener score. Seven patients had moderate dysphagia (baseline MBS of 1-6) and 6 
patients had severe dysphagia (baseline MBS of 7-9). The moderate cohort had an overall 2.57 
(SD = 1.3) reduction in thickener level, while the severe cohort had a 4.83 (SD = 1.8) reduction 
in thickener level (p = 0.03). There was no significant difference between the cohorts in terms 
of sign/symptom reduction: the moderate cohort reduced by 2.85 points while the severe 
cohort reduced by 2.0 points (p = 0.88).  
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Table 3: Patient demographics  
Number of patients 13 
Age at Diagnosis, Months (mean, SD) [R] 21.6 (10.1) [11, 47] 
Gender (males, %) 5 (38.4) 
Ethnicity (N, %) 
Caucasians 
African American 
Hispanic 
Unknown 
 
7 (53.8) 
2 (15.3) 
3 (23.1) 
1 (7.7) 
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Figure 1: Thickener levels before and after therapy 
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Discussion 
DINs are an emerging topic in aerodigestive disease in pediatrics. While many cohort studies 
have analyzed LC1s as a whole, further sub-classification has not been performed to isolate the 
role of DINs in aerodigestive disease. One study on LC1 did mention including DIN patients 
(described as “low inter-arytenoid height”)[5], but no subgroup analysis was performed on that 
set of patients to draw any meaningful conclusions specifically for DIN patients. A recent review 
article examined previous studies on IL as treatment option for LC1[6], but none of the 
published studies delved into the discussion of patient selection and classifying the LC1s further 
into sub-categories[15,16,17,18]. Whether DIN patients were included in these studies is 
unclear, which left the question of what treatment modalities are suited for DIN patients 
specifically. The purpose of this study aimed to answer this question.  
Patients with laryngeal clefts more often than not have other congenital abnormalities, 
coincident pathologies, and syndromic associations[11,25]. Our study was unique in that 
patients with major contributing comorbidities such as neurodevelopmental delay and prior 
esophageal manipulation were excluded. Of the other less severe comorbidities reported, GERD 
had a particularly higher incidence among our patients at 76.9%. Previous literature cites the 
incidence of GERD in LC1 patients anywhere from 21% to 59%[5,26]. While this may be simply 
due to sampling error, it can also be explained by the fact that some patients in our cohort 
were started on PPIs prophylactically rather than due to GERD symptoms. They then continued 
the medication when EGD revealed mild esophagitis. Nevertheless, GERD remains a significant 
contributor to these patients’ disease process and should be addressed appropriately.  
The results of this study show that combination therapy with IL and thickener wean shows 
promise in young children who present with DA associated with DIN. We observed this through 
both objective measure via thickener level needed to prevent aspiration/penetration and 
subjective measure via parent reporting of signs and symptoms. After receiving the dual 
therapy, patients were able to tolerate thinner liquids which allowed them to reduce their 
dependence on thickeners, ultimately reducing their DA-related signs/symptoms. These results 
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also verify the findings of our previous pilot study, in that DIN patients with more severe 
dysphagia experience more benefit from IL[27].  
Feeding therapy remains integral in the treatment of patients with DINs/LC1s, especially 
considering how such defects affect all phases of swallowing[9]. Using tolerance to thinner 
liquid consistencies as an endpoint is not a new concept, and many studies on laryngeal clefts 
use similar designs for their outcome measure [17,18,21,22]. We used a systematic thickener 
wean to serve both a therapeutic purpose as well as to monitor progress of treatment. Wolter 
et al. [24] demonstrated thickener weaning to be a successful management technique in most 
children with DA and predicted that it allowed the swallowing mechanism to steadily adapt to 
the consistency changes over time. Of note, the scale in table 1 does not represent equal 
intervals between each numerical score, but was rather designed to obtain measurable 
information for this study as described in the methods section.  
IL is a safe and efficacious treatment option that has emerged more recently. A review of 
studies utilizing IL for LC1/DIN reported 1 complication from a total of 166 patients[6]. It was 
noted that there were instances of no improvement with IL, and sometimes slight worsening of 
symptoms. However, many of the studies included in this review included patients with 
significant comorbidities which may be influencing the outcome. In our cohort of patients with 
no significant comorbidities, no complications occurred and all patients experienced clinical 
improvement.  
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Future Directions 
Going forward, there are several ways to use this data to direct future studies, based on our 
weaknesses. To begin, this study was retrospective in nature and dealt with a small sample size. 
The limitation to the number of patients resulted from the fact that the current version of TWP 
was not implemented in PCH until January 2015, so inclusion of prior patients would have 
deviated from the standardized protocol which was integral to our primary outcome measure. 
Originally, this study was designed to include a comparative arm with patients treated with 
TWP alone. Due to system issues related to timely third party authorizations for TWP with a SLP 
to apply protocol, a prospective study was postponed until infrastructure and system details 
were secured for flawless TWP post-aerodigestive evaluation. Our group is considering a shift in 
the clinical paradigm of DA in young children, where DIN is considered a functional defect and 
therefore the next step is a randomized controlled prospective study of TWP and IL. 
Furthermore, because no formal description of DIN has been established, the diagnosis remains 
subjective. At the PCH ADC, 2 otolaryngologists made the diagnosis of DIN based on visual 
characteristics and palpation of the interarytenoid area which carries subjectivity. Future work 
could benefit from formal criteria to diagnose DIN and from the development of diagnostic 
tools to help better direct patient selection.  
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Conclusions 
Overall, our findings suggest that treatment of DIN associated DA is possible with a combination 
of thickeners and IL. This leads to significant clinical improvements of symptoms in young 
children, along with their ability to tolerate thinner feeds. Although DIN has not been described 
much in literature, these results suggest that DIN is a contributing factor to the underlying 
pathology in this subset of DA patients. Future work is necessary to determine whether the 
benefit from this treatment is truly superior to either surgical or medical treatment alone.   
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